Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.

Wang, Jinwan; Xu, Ruihua; Li, Jian; Bai, Yuxian; Liu, Tianshu; Jiao, Shunchang; Dai, Guanghai; Xu, Jianming; Liu, Yunpeng; Fan, Nanfeng; Shu, Yongqian; Ba, Yi; Ma, Dong; Qin, Shukui; Zheng, Leizhen; Chen, Weichang; Shen, Lin

doi:10.1007/s10120-015-0457-4

Public

Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.

Shared by NobleBlocks on Jan 1, 2016 • 12:00 AM UTC

Authors:

Jinwan Wang

Ruihua Xu

Jian Li

Abstract

BACKGROUND: The V325 study showed that docetaxel, cisplatin, and fluorouracil (DCF) prolonged overall survival (OS) of patients with advanced gastric cancer, but with a high incidence of dose-limiting toxicities. We investigated the efficacy and safety of a modified DCF (mDCF) regimen for Chinese pa...

Subject

Advanced gastric cancer

Modified docetaxel and cisplatin plus fluorouracil regimen

Overall survival

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!